RE-LY Heart Failure Subgroup Bleeding Score Calculator

Clinical calculation support · Verify results before clinical use

Patient assessment

Use the patient's current clinical information.

Clinical calculator
Required; enter 18–120 years.
Optional. Anemia threshold: <13 g/dL in men or <12 g/dL in women.
Optional; used in ORBIT and ATRIA when provided.
Optional; used for the HEMORR₂HAGES platelet component.
Reset form

How to interpret these scores

Bleeding scores can help structure review of modifiable risk factors but should not be used alone to withhold anticoagulation. The scores were developed in atrial-fibrillation populations and their performance may differ by treatment, comorbidity, and clinical setting.

Risk-reduction checklist

  • Improve blood-pressure control and review renal and hepatic function.
  • Confirm the indication and duration for antiplatelet therapy; avoid unnecessary combination antithrombotic treatment.
  • Review NSAIDs, alcohol use, anemia, prior bleeding, and falls.
  • For vitamin K antagonist therapy, assess INR control and time in therapeutic range.
  • Reassess risk factors over time and apply clinical judgement to the individual patient.

Important limitations

The input set does not capture every variable in the original derivation datasets. HAS-BLED drug exposure is represented by antiplatelet and NSAID selections; ORBIT uses antiplatelet therapy specifically. The anemia definition here uses hemoglobin only, not hematocrit or history of anemia. Treat outputs as a bedside approximation when these data are unavailable.

References

HAS-BLED validationLip GYH, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2011;57:173–180. doi:10.1016/j.jacc.2010.09.024
ORBIT bleeding scoreO’Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015;36:3258–3264. doi:10.1093/eurheartj/ehv476
ATRIA bleeding scoreFang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA study. J Am Coll Cardiol. 2011;58:395–401. doi:10.1016/j.jacc.2011.03.031
HEMORR₂HAGESGage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation. Am Heart J. 2006;151:713–719. PubMed record
RE-LY contextProietti M, Hijazi Z, Andersson U, et al. Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial. J Intern Med. 2018;283:282–292. doi:10.1111/joim.12702
Clinical disclaimer: This educational calculator provides score point totals, not a diagnosis or a validated individualized probability of bleeding. It is not specifically validated as a heart-failure subgroup prediction model. Confirm definitions against the original instruments, consider the patient's full clinical context, and use current local guidelines and clinician judgement for treatment decisions.